These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 29421214)
1. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver. Plöger GF; Hofsäss MA; Dressman JB J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214 [TBL] [Abstract][Full Text] [Related]
2. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Lindenberg M; Kopp S; Dressman JB Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954 [TBL] [Abstract][Full Text] [Related]
3. Is the full potential of the biopharmaceutics classification system reached? Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971 [TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. Cristofoletti R; Chiann C; Dressman JB; Storpirtis S J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377 [TBL] [Abstract][Full Text] [Related]
5. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. Davit BM; Kanfer I; Tsang YC; Cardot JM AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914 [TBL] [Abstract][Full Text] [Related]
7. Commonality between BCS and TCS. Shah VP; Rădulescu FŞ; Miron DS; Yacobi A Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656 [TBL] [Abstract][Full Text] [Related]
8. The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs. Sediq A; Kubbinga M; Langguth P; Dressman J J Pharm Sci; 2014 Jan; 103(1):65-70. PubMed ID: 24338749 [TBL] [Abstract][Full Text] [Related]
9. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence. Daousani C; Macheras P Int J Pharm; 2015 Jan; 478(2):606-9. PubMed ID: 25437115 [TBL] [Abstract][Full Text] [Related]
11. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251 [TBL] [Abstract][Full Text] [Related]
12. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies. Mishra V; Gupta U; Jain NK Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933 [TBL] [Abstract][Full Text] [Related]
13. Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification. Miranda C; Pérez-Rodríguez Z; Hernández-Armengol R; Quiñones-García Y; Betancourt-Purón T; Cabrera-Pérez MÁ AAPS PharmSciTech; 2018 May; 19(4):1693-1698. PubMed ID: 29532425 [TBL] [Abstract][Full Text] [Related]